// App-Quantinova.ai

403 : Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

Researchers

Presenter

  • Timothy Price

Principal Investigators

  • Sant Chawla

  • Gerald Falchook

  • Hans Prenen

  • Iwona Lugowska

  • Vivek Subbiah

  • Jose Monzon

  • Yuichi Ozawa

  • Tobias Arkenau

  • Caio Rocha Lima

  • Yasutoshi Kuboki

  • Tomohiro Nishina

  • Mun Hui

  • Erik Rasmussen

  • Hansen Wong

  • Saltanat Najmi

  • Nooshin Sadraei

Medical Centers

  • University of Adelaide, The Queen Elizabeth Hospital Campus, CALHN, Woodville, Australia

  • Oncology, Sarcoma Oncology Center, Santa Monica, CA, USA

  • Sarah Cannon Research Institute, Denver, CO

  • University Institution Antwerp, Antwerp, Belgium

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • The University of Texas MD Anderson, Houston, TX, USA

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • Wakayama Medical University Kihoku Hospital, Ito, Wakayama, Japan

  • Sarah Cannon Research Institute UK, London, UK

  • Wake Forest Baptist Health, Miami, FL, USA

  • National Cancer Center, EPOC, Chiba, Japan

  • National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

  • Chris O'Brien Lifehouse, Camperdown, Australia

  • Amgen Inc., New York, NY, USA

Locations

  • Australia

  • United States

  • Belgium

  • Poland

  • Canada

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved